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Abstract
Intratumoral heterogeneity has been suggested to be an important resistance mechanism
leading to treatment failure. We hypothesized that radiologic images could be an alternative
method for identification of tumor heterogeneity. We tested heterogeneity textural parame-
ters on pretreatment FDG-PET/CT in order to assess the predictive value of target therapy.
Recurred or metastatic non-small cell lung cancer (NSCLC) subjects with an activating
EGFR mutation treated with either gefitinib or erlotinib were reviewed. An exploratory data
set (n = 161) and a validation data set (n = 21) were evaluated, and eight parameters were
selected for survival analysis. The optimal cutoff value was determined by the recursive par-
titioning method, and the predictive value was calculated using Harrell’s C-index. Univariate
analysis revealed that all eight parameters showed an increased hazard ratio (HR) for pro-
gression-free survival (PFS). The highest HR was 6.41 (P<0.01) with co-occurrence (Co)
entropy. Increased risk remained present after adjusting for initial stage, performance status
(PS), and metabolic volume (MV) (aHR: 4.86, P<0.01). Textural parameters were found to
have an incremental predictive value of early EGFR tyrosine kinase inhibitor (TKI) failure
compared to that of the base model of the stage and PS (C-index 0.596 vs. 0.662, P = 0.02,
by Co entropy). Heterogeneity textural parameters acquired from pretreatment FDG-PET/
CT are highly predictive factors for PFS of EGFR TKI in EGFR-mutated NSCLC patients.
These parameters are easily applicable to the identification of a subpopulation at increased
risk of early EGFR TKI failure. Correlation to genomic alteration should be determined in
future studies.







Citation: Park S, Ha S, Lee S-H, Paeng JC, Keam B,
Kim TM, et al. (2018) Intratumoral heterogeneity
characterized by pretreatment PET in non-small cell
lung cancer patients predicts progression-free
survival on EGFR tyrosine kinase inhibitor. PLoS
ONE 13(1): e0189766. https://doi.org/10.1371/
journal.pone.0189766
Editor: Juri G. Gelovani, Wayne State University,
UNITED STATES
Received: February 5, 2017
Accepted: December 1, 2017
Published: January 31, 2018
Copyright: © 2018 Park et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This study was supported by a grant
from the Ministry for Health, Welfare & Family
Affairs (HI13C0015) and the Innovative Research
Institute for Cell Therapy (A062260), Republic of
Korea. The funders had no role in study design,
data collection and analysis, decision to publish, or
preparation of the manuscript.
Introduction
Although non-small cell lung cancer (NSCLC) is a leading cause of cancer-related death and
comprises 23% of total cancer deaths[1], a subpopulation with activating epidermal growth
factor receptor (EGFR) mutations have demonstrated prolonged progression-free survival
(PFS) with the development of EGFR tyrosine kinase inhibitors (TKI)[2–4]. However, target
therapies which focus on a critical survival pathway do not benefit all patients. This phenome-
non may be partially explained by intratumoral heterogeneity, which refers to the existence of
subpopulations of distinct cancer cells within a tumor[5]. For this reason, it has been a
research focus[6] in this current era of target therapy[7–10]. Moreover, a small population of
sub-clone with genetic heterogeneity remains challenging to identify.
Due to the disadvantages of executing multiple biopsies and the high cost of genomic evalu-
ation, alternative approaches to detect intratumoral heterogeneity through non-invasive imag-
ing have been investigated[11], and attempts to determine genomic variation by interpreting
large amounts medical imaging data have been conducted[12]. Conventional positron emis-
sion tomography/computed tomography (PET/CT) indices, such as average standardized
uptake value (SUVaverage) and maximum standardized uptake value (SUVmax), are also used as
parameters of inter-tumor heterogeneity[13, 14]. By extension, metabolic heterogeneity char-
acterized by local and regional textural parameters by 2[18F] fluoro-2-deoxy-D-glucose (FDG)
uptake in pretreatment FDG-PET/CT allows the prediction of chemotherapeutic response[15,
16], disease progression after concurrent chemoradiotherapy[17], and overall survival[18–20].
Moreover, these parameters have demonstrated significant predictive value in NSCLC patients
who have undergone curative resection[21].
To date, despite the clinical importance of identifying intratumoral heterogeneity, limited
adjuvant methods have been investigated to predict the response to target therapy. In this
study, we assessed the clinical value of local and regional textural parameters from a pretreat-




NSCLC patients (n = 2012) who were treated with either gefitinib or erlotinib from July 2002
to September 2014 in Seoul National University Hospital (SNUH) were reviewed. Subjects
who had not been tested for EGFR genotype prior to treatment (n = 1047) and subjects who
had been tested but lacked an EGFR mutation (n = 274) were excluded. Inclusion criteria were
as follows: (i) subjects with exon 19 deletion or exon 21 point mutation [L858R or L861Q] con-
firmed either by peptide nucleic acid clamping or by DNA sequencing; and (ii) subjects with
pre-EGFR TKI treatment FDG-PET/CT scan available.
To avoid any potential bias due to different PET-CT matrix size, we selected 200 × 200
matrix size which contains most number of patients for the exploratory subset (n = 261) and
256 × 256 for the validation subset (n = 112). Subjects with other than above two matrix sizes
were excluded from analysis (n = 282). The subjects were further selected based on the avail-
ability of pretreatment FDG-PET/CT scan and total of 182 subjects’ data, 200 × 200 matrix size
(n = 161) and 256 × 256 matrix size (n = 21), was used for the final analysis. (Fig 1)
Clinical data collection
Medical history, pathology, and imaging data were reviewed retrospectively. The 7th edition of
the American Joint Committee on Cancer Staging manual was used to define initial stage, and
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treatment response was evaluated by comparing post-treatment CT to pretreatment CT in
accordance with the Response Evaluation Criteria in Solid Tumor (RECIST) ver. 1.1[22]. Sur-
vival data were collected from the Korean death registry. All data were acquired under the
supervision of the Institutional Review Board of SNUH (SNUH IRB No.1411-026-623). This
study is classified as a retrospective observational study which IRB waives patient permission
for the review of the de-identified medical record.
FDG-PET/CT imaging protocol
After 6 h of fasting, FDG-PET/CT images were acquired using dedicated FDG-PET/CT scan-
ners (Biograph 40 mCT, Biograph 64 mCT and Biograph TruePoint; Siemens, Erlangen, Ger-
many). One hour prior to scanning, 5.18 MBq/kg of 18F-FDG was injected intravenously. The
fasting blood glucose level was maintained at7.8 mmol/L. A pre CT scan was obtained for
attenuation correction prior to a PET scan. An ordered subset-expectation maximization algo-
rithm was used for reconstruction and detailed settings were: (i) for Biograph 40 (n = 78) and
Biograph 64 (n = 83) mCT scanners, 200 × 200 matrix, time-of-flight, 2 iterations and 21 sub-
sets were adapted; (ii) for Biograph TruePoint scanner (n = 21), 256 × 256 matrix, 4 iterations
and 8 subsets were adapted.
FDG-PET/CT image analysis
FDG-PET/CT images report were reviewed twice by two different nuclear medicine physicians
by one physician validate the other physician’s imaging report. SUV was calculated as the ratio
between concentrated radioactivity on the tissue (kBq/mL) and the injected dose per weight
(kBq/g). FDG-PET/CT image analysis was conducted by PMOD (PMOD Technologies Ltd.,
Switzerland) and CGITA v.1.3 software (Chang-Gung Memorial Hospital, Taiwan). The steps
for acquisition of heterogeneity textural parameters were: FDG-PET/CT scan acquisition, VOI
(volume of interest) placement, tumor segmentation, resampling, and feature extraction by
textural analysis (Fig 2). After FDG-PET/CT scan acquisition, a VOI was placed on the pri-
mary tumor in most cases. In the eight cases with no available lung mass for analysis, a VOI
was placed on metastatic lesions in skeletal regions such as the spine, ribs, and femur. The
Fig 1. Flow chart of patient selection. Abbreviations: NSCLC = non-small cell lung cancer, EGFR = epidermal growth factor receptor, PET = positron emission
tomography, CT = computed tomography.
https://doi.org/10.1371/journal.pone.0189766.g001
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tumor was segmented with a predetermined cutoff value of SUV 3.5. Subsequently, gray levels
of the segmented tumor were resampled to standardize the range of values. This was done to
reduce noise in the delineated tumor and to normalize the scales among different cases[15].
Sixty-four gray levels were adapted for an optimal resampling scale in this study. Compared to
other sampling scales, this attained higher reproducibility, robustness, and the potential for
information complementary to MV[23–25].
Textural analysis
Multiple mathematical models for textural analysis were applied. Based on the scales of analy-
sis, statistics-based texture analyses were composed of global, local, and regional scales[26]. It
was unclear which scale was appropriate for representing intratumoral heterogeneity to predict
PFS of EGFR TKI in cases of TKI treatment for NSCLC patients. Therefore, we included most
of the texture features that had been reported in previous studies to be predictive of treatment
response by textural analyses. Histogram-based parameters (global features) and reconstructed
matrices, which described the relationship between each of the voxels, were applied to calculate
heterogeneity. Co-occurrence (Co) matrix based parameters and Neighborhood intensity dif-
ference (NID) matrix based parameters were local scale features used to describe the frequency
of certain relationships between two voxels of intensity. Two regional matrices, a voxel align-
ment (VA) matrix, and an intensity size zone (ISZ) matrix, were used to calculate regional
scale parameters in this study. All parameters and their abbreviations are displayed in S1
Table. Detail methods of calculating parameters described in Fig 3, S1 Table and S1 Fig were
described in a review article by Cook et al[27].
Statistical analysis
The baseline demographics of the subjects in the exploratory and validation datasets were ana-
lyzed with descriptive statistics. Spearman’s rank correlation coefficients of each textural
parameter were calculated by comparing texture parameters to the Co entropy value, which is
defined as calculated randomness of voxel intensity and has been proposed as a useful parame-
ter for measurement of intratumoral heterogeneity. A Bonferroni correction was used and
parameters with P 0.001 were considered as statistically significant. Four textural parameters
from the group with positive correlation to Co entropy and four parameters from the group
with negative correlation were selected from different feature parents.
Rather than using defined PFS time point for the evaluation, optimal cutoff values were
established by a recursive partitioning method[28], which satisfied the highest hazard ratio
with P 0.05 and PFS were calculated for groups below and above cut-off value. Applying
Fig 2. Schematic flow of textural analysis. (A) FDG-PET/CT scan acquisition. (B) Placement of a volume of interest on the primary tumor. (C) Tumor
segmentation by isocontour with SUV of 3.5 (D) Gray scale resampling and texture feature extraction in global, local, and regional scales. Abbreviations: Co = Co-
occurrence, NID = Neighborhood intensity difference, VA = Voxel alignment, ISZ = intensity size zone.
https://doi.org/10.1371/journal.pone.0189766.g002
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optimal cutoff values to the survival analysis, hazard ratios (HR) for PFS were calculated by
Cox proportional-hazard regression analyses, and Kaplan-Meier curves were used to portray
treatment failure. In this study, we have defined early EGFR TKI failure as the group with
shorter PFS using the optimal cutoff values. PFS was calculated from the date of initiation of
EGFR TKI treatment to the date of cancer progression or all-cause mortality. Multivariate
analysis was performed using parameters satisfying P 0.05 following univariate analysis or
parameters considered to be clinically significant. Incremental predictive value of PFS of
EGFR TKI failure was determined by comparing Harrell’s C-index to different Cox propor-
tional hazard regression models[29].
Statistical analyses were conducted with STATA version 12.1 software (StataCorp, College
station, TX, USA) and R-3.1 for Windows (Ross Ihaka and Robert Gentlemen, University of
Auckland, New Zealand). All results with a two-tailed P 0.05 were considered to be
significant.
Fig 3. Spearman’s rank correlation coefficients of textural parameters compared to the value of co-occurrence entropy. Abbreviations are listed in S1 Table.
https://doi.org/10.1371/journal.pone.0189766.g003
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Results
Characteristics of the study population
Baseline clinical characteristics of the exploratory and validation datasets are shown in
Table 1. In the exploratory dataset, the median age was 66 (range, 36–88), 34.2% were male,
and 98.8% were diagnosed with adenocarcinoma. The subjects with initial metastatic dis-
ease comprised 85.1% of the exploratory study population and 95.7% of the subjects were
treated with gefitinib. A total of 94.4% were treated with EGFR TKI as first-line treatment,
and the median time difference pretreatment FDG-PET/CT scan to EGFR TKI treatment
was 0.5 (range 0.0–2.7) months in the exploratory dataset and 0.7 (range 0.0–4.0) months in
the validation dataset.




n (%) n = 161 n = 21
Age (Years) median (range) 67 (36–88) 68 (48–82) 0.40
Sex
M 55 (34.2) 4 (19.1) 0.22
F 106 (65.8) 17 (80.9)
Tumor Cell Type
ADC 159 (98.8) 17 (80.9) <0.01
Others 2 (1.2) 4 (19.1)
ECOG PS
0 and 1 140 (87.0) 15 (71.4) 0.06
2, 3 and 4 21 (13.0) 6 (28.6)
Initial Disease Status
Recurred 24 (14.9) 2 (9.6) 0.74
Metastatic 137 (85.1) 19 (90.4)
EGFR MT
Exon 19 87 (54.0) 18 (85.7) 0.01
Exon 21 74 (46.0) 3 (14.29)
EGFR TKI
Gefitinib 155 (95.7) 21 (100,0) 1.00
Erlotinib 7 (4.3) 0 (0.0)
EGFR TKI treatment
1st line 153 (95.0) 18 (85.7) 0.15
2nd line 8 (5.0) 3 (14.3)
TKI response
CR 3 (1.9) 0 (0.0) 0.28
PR 126 (78.3) 15 (71.4)
SD 24 (14.9) 3 (14.3)
PD 7 (4.3) 2 (9.5)
N/A 1 (0.6) 1 (4.8)
Time interval between FDG-PET/CT to treatment (Months)
median (range) 0.5 (0.0–2.7) 0.7 (0.0–4.0) <0.01
Abbreviations: ADC = adenocarcinoma, ECOG PS = Eastern Cooperative Oncology Group Performance Status, EGFR = epidermal growth factor receptor,
TKI = tyrosine kinase inhibitor, CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease
https://doi.org/10.1371/journal.pone.0189766.t001
Intratumoral heterogeneity predict PFS on EGFR TKI
PLOS ONE | https://doi.org/10.1371/journal.pone.0189766 January 31, 2018 6 / 16
Textural parameters associated with early EGFR TKI failure
Spearman’s rank correlation coefficients were calculated by comparing textural parameters
with Co entropy (Fig 3), and the trend of HR for TKI PFS by binary distribution at the upper
and lower 10% and 25% was shown (S1 Fig). Subjects with higher than optimal cutoff values
for Co homogeneity, VA intensity variability, NID busyness and ISZ intensity variability, all
values whose increase represents increased intratumoral heterogeneity, showed increased HR
as PFS of EGFR TKI treatment. Increases in HR were also observed in SUVmax (HR: 2.77, 95%
confidential interval [CI] 1.58–4.87), SUVaverage (HR: 1.64, 95% CI 1.01–2.70), and SUVMV
(HR: 2.89, 95% CI 1.65–5.05). Multivariate analysis was calculated by adjusting for initial
stage, Eastern Cooperative Oncology Group Performance Status (ECOG PS) and SUVMV cate-
gorized by 45 cm3. The results of this analysis exhibited the same tendency in HR (aHR) for
PFS of EGFR TKI (Table 2). However, the aHR for SUVaverage was insignificant after adjust-
ment. Representative images from subjects with short PFS and long PFS of EGFR TKI are pre-
sented in Fig 4.
Incremental predictive value of textural parameters for EGFR TKI failure
When textural parameters were added to the base model, Harrell’s C-index was significantly
greater than the base model in Co homogeneity (0.596 vs. 0.650; P = 0.02), VA intensity vari-
ability (0.596 vs. 0.644; P = 0.03), NID difference busyness (0.596 vs. 0.631; P = 0.05), and VA
short run emphasis (0.593 vs. 0.669; P = 0.01). When a Cox regression model adjusted for both
MV and textural parameters was compared to the base model, a significant incremental pre-
dictive value for PFS of EGFR TKI treatment was demonstrated in all parameters (Table 3).
Association of textural parameters with early EGFR TKI failure in
validation dataset
All eight textural parameters showed increased hazard ratios with survival analysis for PFS by
binary distribution at either the upper or the lower third value (Fig 5). However, only ISZ
intensity variability reached statistical significance (HR: 3.80, 95% CI 1.24–11.60, P = 0.02).
Discussion
In our dataset of NSCLC subjects with activating EGFR mutations, we demonstrated an inde-
pendent predictive value of intratumoral heterogeneity for early EGFR TKI failure measured
by textural parameters in pretreatment FDG-PET/CT. Given that a pretreatment FDG-PET/
CT scan is recommended during the initial staging work-up,[30] our results have clinical
implications for identifying a high-risk subpopulation for EGFR TKI treatment.
A clonal evolution model involving Darwinian natural selection has been suggested as an
important cancer progression model.[31] Evidence supporting this model has been observed
using next-generation sequencing (NGS) techniques, which allow the identification of geno-
mic heterogeneity for a variety of cancers.[7, 32–34] Although a clone with an actionable
mutation may be dominantly present in the trunk mutation of a tumor, a minority subpopula-
tion with a branch mutation may contribute to treatment resistance.[35] Understanding that
EGFR TKI treatment focuses on interrupting a tumor’s dependency on an EGFR dependent
survival pathway (identified in a specific sub-clone selected by a biopsy) may result in an
unidentified resistant mutant clone, such as T790M,[36] being a likely cause of treatment fail-
ure.[10] However, due to the limited representative value of a single tissue biopsy, a radioge-
nomic prediction model in which tumor heterogeneity is detected using metabolic activity
measured by FDG-PET/CT has been suggested.[37, 38] An initial approach using standard
Intratumoral heterogeneity predict PFS on EGFR TKI
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parameters of FDG uptake was based on the hypothesis that FDG uptake shows not only fac-
tors related to metabolism, but also multiple factors related to intratumoral heterogeneity[39],
especially hypoxia.15,26 Moreover, a genomic alteration in NSCLC was also associated with
FDG uptake, and FDG uptake correlated with tumor aggressiveness and a poor prognosis of
survival.[40] Therefore, approaches evolved to assess metabolic heterogeneity using textural
parameters of FDG-PET/CT images, and these approaches were proved to have independent
predictive value regarding treatment outcome.[15, 16, 18–20] Overall, intratumoral heteroge-
neity identified by metabolic texture analysis on FDG-PET/CT might be useful as a radioge-
nomic marker of global intratumoral genetic heterogeneity.
Table 2. Cox proportional regression analysis of the optimal cutoff value calculated from the exploratory dataset.
Number of patients PFS
Optimal cutoff Above cutoff Below cutoff Uni-variate analysis Multi-variate analysisc)

























































SUV(metabolic volume) 109 24 (14.8) 137 (85.2) 2.89
(1.65–5.05)
<0.01a) - -
SUV(metabolic volume) categorized by 45cm3 45 51 (31.7) 110 (68.3) 1.88
(1.15–3.10)
0.01a) - -
Initial disease status - - - 2.01
(0.86–4.65)
0.11 - -
ECOG PS - - - 2.28
(1.24–4.20)
0.01 - -
Type of TKI - - - 0.72
(0.10–5.23)
0.74 - -
Type of EGFR mutations - - - 0.94
(0.74–1.20)
0.62 - -
Initial disease status was divided into two groups: recurred and metastatic.
ECOG PS was divided into two groups: subjects with ECOG PS 0 and 1 vs. subjects with ECOG PS 2, 3, and 4.
a) P calculated by Cox proportional regression analysis compared subjects above the optimal cutoff value to those below the optimal cutoff value
b) P calculated by Cox-proportional regression analysis compared to subjects with below optimal cutoff value to subjects with above optimal cutoff value
c) Multivariate analyses were conducted for each parameter adjusted for ECOG PS, SUV metabolic volume (categorized) and initial disease status
Abbreviations: PFS = progression free survival, HR = hazard ratio, CI = confidential interval, aHR = adjusted hazard ratio, SUV = standardized uptake value
https://doi.org/10.1371/journal.pone.0189766.t002
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Conventional FDG-PET/CT parameters including SUVmax, SUVaverage, MV, and total
lesion glycolysis have been evaluated as prognostic factors for oncological treatment. [37]
However, these parameters are excessively simple and are insufficient for use in combination
with data from the fields of genomics, metabolomics, or proteomics. Conversely, radiomic
information from FDG-PET/CT, which entails large amounts of data extracted by textural
analysis, is expected to be of use in combination with genomic, metabolic, and proteomic data.
[27] Nevertheless, the high correlation and dependency of each metabolic heterogeneity tex-
tural parameter and MV is an unresolved issue. This correlation and dependency are impor-
tant for textural analysis as it produces complementary information for conventional
Fig 4. Representative images from the exploratory dataset (200 x 200 matrix). Representative images of two patients who had metabolic volumes with different
heterogeneity textural parameters. Patients with increased intratumoral heterogeneity by textural parameters showed poor progression free survival. Panel A & B. A
51-year-old woman with 4.7 months of progression free survival. (A) Pre-treatment FDG-PET/CT images (SUVmax 34.1, metabolic volume 109.3 cm3) EGFR exon 19
micro-deletion mutation; Co entropy: -82302; Co homogeneity: 6951; VA intensity variability: 299; VA short run emphasis: 0.458; NID busyness: 1.170; NID contrast:
4.85 x 10–5; ISZ intensity variability: 964.0; and ISZ high intensity zone emphasis: 472.1. (B) Post-treatment FDG-PET/CT images after 4.7 months (SUVmax 36.7,
metabolic volume 358.5 cm3) Panel C & D. A 71-year-old woman with 15.4 months of progression free survival. (C) Pre-treatment FDG-PET/CT images (SUVmax
16.0, metabolic volume 95.1 cm3) EGFR exon 19 micro-deletion mutation; Co entropy: -53663; Co homogeneity: 5156; VA intensity variability: 680; VA short run
emphasis: 0.387; NID busyness: 1.012; NID contrast: 7.98 x 10–5; ISZ intensity variability: 603.8; ISZ high intensity zone emphasis: 530.2. (D) Post-treatment FDG-PET/
CT images after 2.8 months (SUVmax: 6.0, metabolic volume: 4.2 cm3). Abbreviations: Co = co-occurrence,VA = voxel alignment, NID = neighbor intensity-difference,
ISZ = intensity size-zone.
https://doi.org/10.1371/journal.pone.0189766.g004
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parameters.[24] Controversy exists regarding the optimal MV cutoff to assure complementary
information of intratumoral heterogeneity. Most of the textural parameters have a high posi-
tive correlation to MV because increased tumor size causes an increase of hypoxia and necro-
sis, which results in greater tissue complexity. However, this positive relationship is weakened
when the tumor increases beyond a certain size. For this reason, we initially included all the
data into the analysis regardless of MV. Independency and complementary characteristics of
intratumoral heterogeneity features to MV were tested by multivariate analysis with catego-
rized MV. A conservative cut off value of 45 cm3 was applied to MV.[41]
In this study, all subjects had documented EGFR mutations, but treatment response varied
from 0.5 to 32.4 months. To validate our hypothesis, it was inevitable for authors to incorpo-
rated number of assumptions and technical approaches for the analyses. The initial approach
was choosing a key representative marker. Co entropy was chosen in this study based on previ-
ous analyses which demonstrated its value as a relatively representative marker of random
FDG consumption on a local scale and used as a reference parameter to identify the risk popu-
lation.[15]. Next approach was conducted to minimize the potential bias due to small tumor
volume. Hence, metabolic volume was adjusted to exclude the possible bias from a small
tumor volume by applying categorized MV with a cutoff of 45 cm3 to multivariate analysis.
[41] Finally, validation process was conducted using a different matrix size. Due to the limited
number of validation datasets, the cutoff was arbitrarily set at the upper or lower third of the
Table 3. Incremental predictive value of textural parameters for EGFR TKI failure.
Base model Base model adjusted with textural
parametersa)
Base model adjusted with textural
parameters and metabolic volume b)
Harrell’s C-index
(95%CI)
P (vs. Base model) P (vs. Base model)






























































- - - -
a) Harrell’s C-index calculated by Cox-proportional regression models adjusted for initial disease status, and ECOG PS
b) Harrell’s C-index calculated by Cox-proportional regression models adjusted for initial disease status, ECOG PS, and SUV metabolic volume
Abbreviations: SUV = standardized uptake value, ECOG PS = Eastern Cooperative Oncology Group Performance Status
https://doi.org/10.1371/journal.pone.0189766.t003
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data to verify that the response tendency and the risk trend was in accordance with the explor-
atory dataset (Fig 5).
Throughout this observation, we have demonstrated the potential predictive value of intra
tumoral heterogeneity characterized by pretreatment FDG/PET-CT parameters which could
provide additional value to the real clinical practice. Hence, authors carefully recommend two
parameters, Co-occurrence which has demonstrated the highest HR even adjusted with ECOS
PS, metabolic SUV and initial stage, and ISZ intensity variability which was statistically signifi-
cant in validation dataset, as an initial approach to predict the response of EGFR TKI through
FDG/PET-CT.
This study has some limitations. It was retrospectively designed and the statistical power is
insufficient due to the limited number of subjects in the validation dataset. However, we speci-
fied the criterion for the inclusion population with a comprehensive review of clinical data. A
limited population limits the ability of statistical analysis to determine the optimal cutoff value
and appropriate textural parameters. In addition, the validation dataset was acquired from a
population with a different matrix size. Our hypothesis was based on previous studies which
reported that tumor heterogeneity can be visualized with radiologic imaging.[27] In order to
confirm a correlation to genomic heterogeneity, each genomic profile from multiple biopsies
conducted on a single tumor mass should be directly compared to the textural parameters
acquired from radiological imaging. However, considering that target therapy is performed on
candidates unsuitable for surgical resection, acquiring multiple samples for validation is
impracticable. Last but not least, FDG-PET/CT has a fundamental limitation as a tailored pre-
dictive modality since its image reflects various tissue reactions which could weaken a repre-
sentative value of our textural parameters. [42]
Conclusions
Our study indicates that pretreatment metabolic textural parameters can be used as predictive
markers for PFS of EGFR TKI in NSCLC with an activating EGFR mutation. Pretreatment
metabolic heterogeneity should be more carefully evaluated and subjects with increased meta-
bolic heterogeneity should be considered as a high-risk subpopulation for early EGFR TKI fail-
ure. Future studies should evaluate any correlation to genomic alteration.
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S1 Fig. Hazard ratios of textural parameters for tyrosine kinase inhibitor progression free
survival: Binary distribution at cutoff value of (A) upper 10%; (B) upper 25%; (C) lower
10%; (D) lower 25%. Abbreviations: Listed in S1 Table.
(TIF)
S1 Table. Abbreviation and definition of each texture parameter, and spearman coefficient
with co-occurrence entropy.
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S2 Table. Raw data used for the analysis.
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Fig 5. Kaplan-Meier curves of progression free survival via representative textural parameters from the validation dataset (n = 21). Binary
distribution with the cutoff of the upper third value in parameter Co heterogeneity (HR: 1.65, 95% CI 0.56–4.83), VA intensity variability (HR 1.63,
95% CI 0.56–4.75), NID busyness (HR: 2.41, 95% CI 0.82–7.10), and ISZ intensity variability (HR: 3.80, 95% CI 1.24–11.6); and with the cutoff of the
lower third value in parameter Co entropy (HR: 1.65, 95% CI 0.56–4.83), VA short run emphasis (HR: 1.99, 95% CI 0.66–6.02), NID contrast (HR:
1.77, 95% CI 0.60–5.18), ISZ high intensity zone emphasis (HR: 2.36, 95% CI 0.77–7.24). Abbreviations: Co = co-occurrence, VA = voxel alignment,
NID = neighbor intensity-difference, ISZ = intensity size-zone.
https://doi.org/10.1371/journal.pone.0189766.g005
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